Start a usable database VivoSense received $ 25 million in a Series A fund led by Perceptive Xontogeny Ventures (PXV) Fund and Debiopharm Innovation Fund.
The company developed Newport Beach, Calif. which can be used in clinical trials to aid in the identification of digital biomarkers. In addition to sensors, the company has a program called VivoSense, which helps interpret sensor data for research and patient care.
“This development initiative from the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund will allow VivoSense to accelerate the development of real -world digital education solutions from visual and remote sensing technologies,” said Dudley Tabakin, CEO of VivoSense, in a statement. “Measurements that are trusted and valued by all stakeholders are the reason all digital health innovations are created. VivoSense is working to see the potential of innovations and innovations. Technology in decision -making and health decision making using real -world data on scale, bringing life -saving drugs to patients who need them most.
AI -supported neurological disease diagnosis Altoida has raised an additional $ 14 million in a Series A expansion round led by M Ventures and Whitecap Venture Partners. This new infusion of money will increase their Series A total to $ 20.3 million.
The brain health industry uses AI, machine learning and augmented reality to aid in the collection of cognitive biomarkers for the diagnosis of neurological disease. On -site data capture can be used to help research and treat people with heart disease.
The start -up in Washington plans to use the new money to help drive its research and expand its product development. The company plans to promote its product in the US and in global markets.
“The Altoida platform is the first to use augmented reality as a means to compare the practices of everyday life, and to leverage AI to develop scientific neurological diagnostics. certified, “Travis Bond, CEO of Altoida, said in a statement. “We are excited to have new publishers joining Altoida and our existing publishers will continue to stand their ground. , network and implementation of innovation in neurology to help us bring our product to patients, suppliers, and researchers in the future. “
Health technology company Zephyr AI has announced a $ 18.5 million revenue round. Lerner Group Investments llC and M-Cor Holdings led the financial round with participation from Allen Y. Chao, AME Cloud Ventures, BoxGroup, MedStar Health, Roger W. Ferguson, Steve Oristaglio, real estate and investors design.
The team is using artificial intelligence and big data to help research the right medicine and drug therapies.
“This significant increase in funding will help us increase our accuracy, including integrating more health care data, refining advanced machine learning features and gaining more accurate information for outcomes. better at patient care and drug awareness, ”said David L. Morgan, CEO of Zephyr AI. in a word.